Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07029399 · ClinicalTrials.gov registry record · Phase 1
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
A Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by NiKang Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 205
- Enrollment target
- 14
- Study locations
NCT07029399: Recruiting Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by NiKang Therapeutics.
NCT07029399 is a Phase 1 study of Ovarian Cancer and Endometrial Cancer that is actively recruiting participants, run by NiKang Therapeutics. The registered enrollment target is 205 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (72% lower). The trial reports 14 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07029399, a Phase 1 study of Ovarian Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by NiKang Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 205 participants
- Enrollment target
- 14
- Study locations
Study Summary
The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main questions to answer include: * What is the recommended dose for expansion and/or Phase 2 * What medical issues/symptoms do participants experience when taking NKT5097
Conditions Studied
Interventions
- DRUG NKT5097 CDK2/CDK4 dual degrader
Study Locations (14)
Texas
- University of Texas Southwestern Medical Center - Dallas
- MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics (START) San Antonio - San Antonio
California
- UC San Diego Moores Cancer Center - La Jolla
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Connecticut
- Yale Cancer Center - New Haven
Florida
- SCRI Florida Cancer Specialists - Sarasota - Sarasota
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- South Texas Accelerated Research Therapeutics (START) Midwest - Grand Rapids
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2025-03-25 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT07029399 shows while recruiting
NCT07029399 is an interventional study that assigns participants to a tested intervention. The registered 205 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (72% lower).
The record links to 7 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which NKT5097 CDK2/CDK4 dual degrader is the first listed.
NCT07029399 lists 14 locations in 12 states (Texas, California, Colorado).
Frequently Asked Questions
What is clinical trial NCT07029399 about?
NCT07029399 is a clinical study titled "A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors". The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main questions to answer include: * What is the recommended dose for...
What is the current status of trial NCT07029399?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 205 participants. The study started on 2025-03-25. Estimated completion is 2027-12-31.
What conditions does trial NCT07029399 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Triple Negative Breast Cancer (TNBC), HR+ HER2- Breast Cancer, Uterine Carcinosarcoma.
What interventions are being tested in trial NCT07029399?
The interventions under investigation include: NKT5097 CDK2/CDK4 dual degrader (DRUG).
Who is sponsoring clinical trial NCT07029399?
This trial is sponsored by NiKang Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07029399 being conducted?
This trial has 14 study locations across California, Colorado, Connecticut, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07029399's enrollment target sits among peer trials
205 95th of 322 higher than 227 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03457493 · 205 participants · Phase 1
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
- NCT05134857 · 205 participants · Phase 2
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
- NCT05181891 · 205 participants · Phase 2
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
- NCT05283811 · 205 participants · NA
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI